The Peptide Field. LL-37: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/ll-37

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=ll-37#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved U.S. LL-37 drug found; FDA plans an advisory-committee discussion before the end of February 2027

Exact product limits: LL-37 is also called ropocamptide. LL-37 amide is a separate FDA substance record, not an exact alias. FDA records and human studies do not show that an online product has the same form, contents, quality, or study material.

Human outcomes: Limited. Wound studies found mixed results. In a later study, 148 people received LL-37 or placebo. It found no clear healing benefit in the full group.

Body effects in people: Limited. The studies do not show how each LL-37 form moves through or affects the body. Researchers used different products in different ways.

What the evidence shows: An early 34-person study of hard-to-heal leg ulcers caused by vein problems reported signs of better healing. A later double-blind study assigned 149 people to topical LL-37 or placebo. Both groups also received compression care. Of those people, 148 received a study treatment. The study found no clear healing benefit in the full group. A later analysis suggested more benefit in people with larger wounds. That was not the study's main test and needs confirmation.

A 25-person study of diabetic foot ulcers used a topical cream for four weeks. It found a higher score for new tissue growth. It found no clear difference in signs of inflammation or the amount of bacteria. A melanoma study enrolled four people in one group. Melanoma is a type of skin cancer. The study cannot prove a cancer benefit.

A 238-person COVID-19 study used a modified bacterium that made a lab-produced form of LL-37. The full group did not clear the virus faster on testing. A group of 48 people started treatment within six days of a positive test.

That group included 20 people assigned to LL-37 and 28 assigned to placebo. The early group had a signal. Patients and researchers knew which treatment was given. The study took place at one medical center and covered the Omicron BA.5.1.3 variant.

What remains unknown: These studies do not prove that LL-37 heals wounds in general, prevents or treats cancer or COVID-19, or improves health for people in general. The wound results differed by study and subgroup. The COVID-19 study did not test a standard LL-37 vial, spray, or plain peptide product.

FDA says there is not enough safety information. It notes possible immune reactions, impurities, and uncertainty about product contents. FDA also cites animal and cell findings about male reproduction and possible tumor growth. These findings do not prove harm in people.

The person or group that asked FDA to consider LL-37 for its pharmacy-compounding list withdrew the request. This is not a ban or a place on the list. FDA plans a discussion with an advisory committee before the end of February 2027. The committee will give advice. It will not make a final FDA decision.

Safety limits: FDA's review does not show that every LL-37 form or product is safe. It includes animal and cell concerns that do not prove risk in people. This guide does not tell readers how much to use, how to take it, where to buy it, which product to choose, or how to treat a condition.

Approval claim: “LL-37 is FDA-approved in the United States.”
Verdict: Misleading. No FDA-approved U.S. LL-37 drug was found when Drugs@FDA was checked for LL-37 and ropocamptide on August 30, 2026. An FDA chemical record identifies a substance. It does not mean that FDA approved a drug.
Evidence basis: Regulatory or product record. Scope: United States approval status as reviewed August 30, 2026.
Claim sources: https://precision.fda.gov/ginas/app/ui/substances/165dbb98-57f3-4152-98b5-a68cd8ccd1d3 https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Approval claim: “FDA has banned LL-37.”
Verdict: Misleading. The person or group who asked FDA to consider LL-37 for its pharmacy-compounding list withdrew the request. That request was called a 503A nomination. Its withdrawal is not a ban. The current federal rule does not list LL-37. FDA plans an advisory-committee discussion before the end of February 2027. That discussion is not a final decision or drug approval.
Evidence basis: Regulatory or product record. Scope: The U.S. pharmacy-compounding status as reviewed August 30, 2026; an advisory discussion is not a final FDA action.
Claim sources: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94155/download?attachment= https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA Global Substance Registration System record for ropocamptide (LL-37). 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/165dbb98-57f3-4152-98b5-a68cd8ccd1d3

U.S. Food and Drug Administration. FDA Global Substance Registration System record for LL-37 amide. 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/4HGQ0GC0N6

PubMed. Human cathelicidin precursor processing to LL-37. 2001. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/11389039/

PubMed. Early randomized trial of topical LL-37 in venous leg ulcers. 2014. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/25041740/

PubMed. Later randomized trial of LL-37 in venous leg ulcers. 2021. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/34687253/

PubMed. Randomized study of topical LL-37 in diabetic foot ulcers. 2023. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/37480520/

ClinicalTrials.gov. LL-37 melanoma study record (NCT02225366). 2014. Accessed 2026-08-30. https://clinicaltrials.gov/study/NCT02225366

PubMed. Engineered Lactococcus lactis producing recombinant LL-37 in COVID-19. 2023. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/37605995/

U.S. Food and Drug Administration. FDA review of safety risks for certain bulk drug substances. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. FDA bulk drug substances nominated for compounding. 2026. Accessed 2026-08-30. https://www.fda.gov/media/94155/download?attachment=

U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting planning. 2026. Accessed 2026-08-30. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee

Electronic Code of Federal Regulations. 21 CFR 216.23 bulk drug substances list. 2026. Accessed 2026-08-30. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

U.S. Food and Drug Administration. FDA drug approvals and databases. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Keep the limits, review date, and sources with this record. Check the current source for changes.